Efficacy and safety by body weight decile in patients treated with tildrakizumab 100 mg for 28 weeks: Pooled data analysis of reSURFACE 1 and reSURFACE 2. J of Skin. 2023;7(2):s136. doi:10.25251/skin.7.supp.136